This study reassessed the classification of HER2-negative breast cancer into HER2-low and HER2-ultralow subcategories, evaluating interobserver variability among pathologists in distinguishing these newly defined expression levels.
The paper abstract/text provided contains no methodological details, sample size, or quantitative results, limiting extraction of specific findings or outcome data.
Pathologists should be aware that subclassifying HER2-negative tumors into HER2-low and HER2-ultralow categories may carry significant interobserver variability, which could affect patient eligibility for emerging HER2-directed therapies.
Explore related topics
